论文部分内容阅读
目的观察肺癌患者化疗过程中应用阿派沙班预防静脉血栓的有效性和安全性。方法选择70例进行化疗且符合入选标准的肺癌患者,将患者进行随机分组,其中化疗联合阿派沙班组36例,化疗组34例,对两组血栓栓塞的发生率进行观察,同时观察血小板降低、出血等安全性指标。结果化疗联合阿派沙班组2例(5.50%)发生血栓栓塞,化疗组10例(29.40%)发生血栓栓塞,两组比较差异有统计学意义(P<0.05);化疗联合阿派沙班组出血2例,血小板减少3例,化疗组中出血2例,血小板减少2例,两组间不良反应比较差异未见统计学意义(P>0.05)。结论肺癌患者化疗联合阿派沙班能降低静脉血栓事件的发生率,同时其不良反应发生率低。
Objective To observe the effectiveness and safety of application of alexipharm in the prevention of venous thrombosis in patients with lung cancer during chemotherapy. Methods Seventy patients with lung cancer who underwent chemotherapy and met the inclusion criteria were randomly divided into three groups: 36 patients in the chemotherapy group and 34 patients in the chemotherapy group, and the incidence of thromboembolism in the two groups was observed. Meanwhile, the incidence of thrombocytopenia , Bleeding and other safety indicators. Results Thromboembolism occurred in 2 patients (5.50%) in chemotherapy combined with epilepsy group, thromboembolism in 10 patients (29.40%) in chemotherapy group, the difference was statistically significant (P <0.05) 2 cases, 3 cases of thrombocytopenia, 2 cases of hemorrhage in chemotherapy group and 2 cases of thrombocytopenia. There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusions Chemotherapy combined with apixaban in patients with lung cancer can reduce the incidence of venous thromboembolic events and the incidence of adverse reactions is low.